Jiyun Cha , Ojin Kwon , Changsop Yang , In-chan Seol , Jung-Hee Jang
{"title":"Herbal medicine treatment patterns for Parkinson’s disease: A nationwide population-based medical claims database in South Korea","authors":"Jiyun Cha , Ojin Kwon , Changsop Yang , In-chan Seol , Jung-Hee Jang","doi":"10.1016/j.eujim.2025.102509","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Parkinson’s disease (PD) is characterized by heterogeneous symptoms and long disease progression and requires individualized treatment. This study aimed to elucidate large-scale herbal medicine patterns according to age, duration of disease progression, and various detailed symptoms of PD, as well as examine comorbidities to build a basis for clinical applications.</div></div><div><h3>Methods</h3><div>We analyzed data from the Korean National Health Insurance System cohort database regarding patients with PD who received herbal medicines between 2014 and 2020. We identified 10,060 patients with various prescription patterns based on age and PD duration. Additionally, to estimate the potential therapeutic mechanisms of insured herbal medicines for the clinical symptoms of PD, we conducted a literature review of the results of clinical and preclinical studies.</div></div><div><h3>Results</h3><div>The overall insurance-covered herbal medicine prescriptions for patients with PD had increased in both the number of prescriptions and patients over time. The herbal medicine use rate in patients with PD was the highest between ages 70 and 79 years and within 3 years of PD onset. Doinseunggi-tang, Haengso-tang, and Palmul-tang were the most frequently used herbal medicines. The most common comorbidities diagnosed along with PD were musculoskeletal and digestive diseases.</div></div><div><h3>Conclusion</h3><div>Some insurance-covered herbal medicines are frequently used among patient groups in a specific age group or duration of disease, and our literature review indicates a correlation between the mechanism of action of these herbal medicines and a specific subgroup of patients with PD. To validate these results and draw meaningful conclusions that reflect the realities of Korean medicine clinical practice, including non-reimbursed treatments, further prospective large-scale clinical trials considering age and disease progression duration are required.</div></div><div><h3>Funding</h3><div>This work was supported by a National Research Foundation of Korea grant.</div></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":"77 ","pages":"Article 102509"},"PeriodicalIF":1.7000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Integrative Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876382025000617","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Parkinson’s disease (PD) is characterized by heterogeneous symptoms and long disease progression and requires individualized treatment. This study aimed to elucidate large-scale herbal medicine patterns according to age, duration of disease progression, and various detailed symptoms of PD, as well as examine comorbidities to build a basis for clinical applications.
Methods
We analyzed data from the Korean National Health Insurance System cohort database regarding patients with PD who received herbal medicines between 2014 and 2020. We identified 10,060 patients with various prescription patterns based on age and PD duration. Additionally, to estimate the potential therapeutic mechanisms of insured herbal medicines for the clinical symptoms of PD, we conducted a literature review of the results of clinical and preclinical studies.
Results
The overall insurance-covered herbal medicine prescriptions for patients with PD had increased in both the number of prescriptions and patients over time. The herbal medicine use rate in patients with PD was the highest between ages 70 and 79 years and within 3 years of PD onset. Doinseunggi-tang, Haengso-tang, and Palmul-tang were the most frequently used herbal medicines. The most common comorbidities diagnosed along with PD were musculoskeletal and digestive diseases.
Conclusion
Some insurance-covered herbal medicines are frequently used among patient groups in a specific age group or duration of disease, and our literature review indicates a correlation between the mechanism of action of these herbal medicines and a specific subgroup of patients with PD. To validate these results and draw meaningful conclusions that reflect the realities of Korean medicine clinical practice, including non-reimbursed treatments, further prospective large-scale clinical trials considering age and disease progression duration are required.
Funding
This work was supported by a National Research Foundation of Korea grant.
期刊介绍:
The European Journal of Integrative Medicine (EuJIM) considers manuscripts from a wide range of complementary and integrative health care disciplines, with a particular focus on whole systems approaches, public health, self management and traditional medical systems. The journal strives to connect conventional medicine and evidence based complementary medicine. We encourage submissions reporting research with relevance for integrative clinical practice and interprofessional education.
EuJIM aims to be of interest to both conventional and integrative audiences, including healthcare practitioners, researchers, health care organisations, educationalists, and all those who seek objective and critical information on integrative medicine. To achieve this aim EuJIM provides an innovative international and interdisciplinary platform linking researchers and clinicians.
The journal focuses primarily on original research articles including systematic reviews, randomized controlled trials, other clinical studies, qualitative, observational and epidemiological studies. In addition we welcome short reviews, opinion articles and contributions relating to health services and policy, health economics and psychology.